Lung Cancer
Conference Coverage
MUC-1 vaccine associated with notable overall survival rates in breast cancer
Patients with HER2-negative early breast cancer receive preoperative standard of care neoadjuvant treatment with or without tecemotide, in new...
Conference Coverage
Neurofilament Light Chain Detects Early Chemotherapy-Related Neurotoxicity
“Nfl after a single cycle could detect axonal degeneration,” says the lead author of new research.
Latest News
New Trials in Lung Cancer: Could Your Patients Benefit?
A number of lung cancer trials are recruiting for NSCLC which is locally advanced, metastatic, and with or without mutations.
Feature
Oncology Mergers Are on the Rise. How Can Independent Practices Survive?
The number of community practices acquired by hospitals nearly tripled from 2010 to 2020, according to a report from COA.
News from the FDA/CDC
FDA Approves Adagrasib for KRAS G12C–Mutated CRC
The agent is the first KRAS inhibitor approved for CRC.
Latest News
Lung Cancer Screening Can Boost Early Diagnosis, Survival
Screened patients had higher rates of diagnosis compared with unscreened patients and better overall survival rates.
Feature
Doctors Endorsing Products on X May Not Disclose Company Ties
Researchers review posts by physicians on X, looking for key words that might indicate that the posts were intended as endorsements of a product...
Conference Coverage
One Patient Changed This Oncologist’s View of Hope. Here’s How.
“How we think about hope directly influences patient care,” according to a professor of clinical medicine at Weill Cornell Medicine in New York...
News from the FDA/CDC
FDA Expands Repotrectinib Label to All NTRK Gene Fusion+ Solid Tumors
The approval was based on a single-arm open-label trial in 88 adults with locally advanced or metastatic NTRK gene fusion solid tumors....
From the Journals
Are Children Born Through ART at Higher Risk for Cancer?
A slight increase in the risk for leukemia was observed in children conceived through IVF or ICSI.
Conference Coverage
‘Practice Changing’ Results for Osimertinib in Unresectable Stage III EGFR+ NSCLC
Study results, including extended median PFS of 33.5 months, are expected to lead to approval in unresectable stage III disease.